Byetta (exenatide) - Altered kidney function, including acute renal failure/renal insufficiency, in patients on Byetta

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: Byetta (exenatide) - Altered kidney function, including acute renal failure/renal insufficiency, in patients on Byetta
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Byetta (exenatide) - Renal Failure

Audience: Endocrine and nephrology healthcare professionals

FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

From April 2005 through October 2008, FDA received 78 cases of altered kidney function (62 cases of acute renal failure and 16 cases of renal insufficiency), in patients using Byetta. Some cases occurred in patients with pre-existing kidney disease or in patients with one or more risk factors for developing kidney problems. Labeling changes include:

Read the complete MedWatch 2009 safety summary, including a link to the Healthcare Professional information sheet, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm


Manage your FDA Subscriptions:


Fight Flu with Facts! Visit flu.gov. Call 800-232-4636. Text FLU to 87000.

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux